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Background	Nosocomial	infection	occurs	commonly	in	intensive	care	units	(ICU).			Although	critical	illness	is	associated	with	immune	activation,	the	prevalence	of	nosocomial	infections	suggests	concomitant	immune	suppression.		This	study	examined	the	temporal	occurrence	of	immune	dysfunction	across	three	immune	cell	types,	and	their	relationship	with	the	development	of	nosocomial	infection.		Methods	A	prospective	observational	cohort	study	was	undertaken	in	a	teaching	hospital	general	ICU.		Critically	ill	patients	were	recruited	and	underwent	serial	examination	of	immune	status,	namely	percentage	regulatory	T-cells	(Tregs),	monocyte	deactivation	(by	HLA-DR	expression)	and	neutrophil	dysfunction	(by	CD88	expression).		The	occurrence	of	nosocomial	infection	was	determined	using	pre-defined,	objective	criteria.			Results	Ninety-six	patients	were	recruited,	of	whom	95	had	data	available	for	analysis.			Relative	to	healthy	controls,	percentage	Tregs	were	elevated	6-10	days	after	admission,	whilst	monocyte	HLA-DR	and	neutrophil	CD88	showed	broader	depression	across	time	points	measured.		Thirty-three	patients	(35%)	developed	nosocomial	infection,	and	patients	developing	nosocomial	infection	showed	significantly	greater	immune	dysfunction	by	the	measures	employed.	Tregs	and	neutrophil	dysfunction	remained	significantly	predictive	of	infection	in	a	Cox	hazards	model	correcting	for	time	effects	and	clinical	confounders	(HR	2.4	(95%	
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CI	1.1-5.4)	and	6.9	(95%	CI	1.6-30)	respectively,	p=0.001).	Cumulative	immune	dysfunction	resulted	in	a	progressive	risk	of	infection,	rising	from	no	cases	in	patients	with	no	dysfunction	to	75%	of	patients	with	dysfunction	of	all	three	cell	types	(p=0.0004).			Conclusions		Dysfunctions	of	T-cells,	monocytes	and	neutrophils	predict	acquisition	of	nosocomial	infection,	and	combine	additively	to	stratify	risk	of	nosocomial	infection	in	the	critically	ill.					Key	Words:	Blood	-	neutrophils,	Blood	-	lymphocytes,	Complications	-	infections,	INTENSIVE	CARE			
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 Many	diseases	that	can	precipitate	the	need	for	exogenous	organ	support	and	admission	to	intensive	care	are	characterized	by	a	profound	systemic	inflammatory	response1,	with	associated	immune	cell	activation	2	and	immune	system-mediated	organ	damage3.		However	it	is	now	increasingly	apparent	that	this	over-exuberant	inflammation	is	accompanied	by	an	equally	vigorous	counter-regulatory	anti-inflammatory	response	4.		The	anti-inflammatory	response	to	the	systemic	inflammatory	response	syndrome	(SIRS)	manifests	across	a	range	of	cellular	actions	and	functions,	involving	both	the	innate	and	adaptive	arms	of	the	immune	system	4		Defects	have	been	noted	in	neutrophils	5-8,	monocytes	9,	T	lymphocytes	10	as	well	as	B	lymphocytes	and	splenic	dendritic	cells	11,12.			The	recent	identification	of	elevated	levels	of	regulatory	helper-T	cells	(Tregs)	in	sepsis	13	is	in	keeping	with	the	supposition	that	much	of	the	immunosuppression	arises	from	the	over-activation	of	counter-regulatory	mechanisms.		In	human	and	experimental	sepsis,	Tregs	impair	the	proliferative	response	of	lymphocytes	
14.			The	demands	of	organ	support	require	the	disruption	of	physical	and	physiological	barriers	through	the	placement	of	devices	such	as	endo-tracheal	tubes.		It	is	thought	that	the	combination	of	immune	vulnerability	and	such	routes	of	microbial	colonization	are	responsible	for	the	high	rates	of	nosocomial	infection	seen	in	critically	ill	patients	15.		These	secondary	infections	typically	
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occur	in	25-35%	of	those	admitted	to	intensive	care	units	(ICUs)	15,	a	rate	that	approaches	that	seen	in	neutropaenia	16.			These	infections	are	associated	with	increased	length	of	stay	17,	morbidity	18	and	mortality	19,	and	therefore	are	of	considerable	concern	to	patients	and	clinicians.		Although	it	seems	plausible	that	the	immune	defects	found	in	critical	illness	are	associated	with	the	acquisition	of	nosocomial	infection,	there	is	little	published	evidence	for	this,	and	what	data	there	are	concentrates	on	single	types	of	immune	cell.		Furthermore	the	temporal	relationship	between	immune	dysfunction	and	nosocomial	infection	is	not	always	clear	6,	limiting	any	inferences	regarding	causality.			This	study	aimed	to	characterise	the	temporal	patterns	of	three	measures	of	immune	dysfunction,	sampling	both	the	innate	and	adaptive	arms	of	the	immune	system,	and	to	derive	potential	new	biomarkers	of	susceptibility	to	nosocomial	infection.		The	cell	types	and	measures	of	dysfunction	chosen	were;	the	level	of			Tregs	as	a	percentage	of	all	CD4+	lymphocytes14,	monocyte	deactivation	assayed	by	monocyte	HLA-DR	expression	9	and	C5a-mediated	neutrophil	dysfunction		assayed	by	surface	CD88	expression	6,	8.			
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Methods	
	
Reagents		Fluorescein	isothiocyanate	(FITC)-conjugated	murine	anti-human	CD4,	allophycocyanin	(APC)-conjugated	murine	anti-human	CD25,	and	phycoerythrin	(PE)-conjugated	murine	anti-human	FOXP3	antibodies	were	obtained	from	eBioscience	(San	Diego,	CA,	USA).		Red	cell	lysis	buffer,	fixation/permeabilization	solution	and	flow	staining	buffer	were	obtained	from	eBioscience.	Alexa	Fluor™	647-conjugated	murine	anti-human	CD88	antibodies	were	obtained	from	AbD	Serotec	(Abingdon,	UK),	and	QuantiBRITE	monocyte	HLA-DR	assay	was	obtained	from	Becton	Dickson	Biosciences	(Oxford,	UK).	Tri-colour	(TC)-conjugated	murine	anti-human	CD16	and	CD62L,	FITC-conjugated	murine	anti-human	CD11b	and	CD14,	and	PE-conjugated	murine	anti-human	CD3	and	CD64	were	obtained	from	Invitrogen	(Paisley,	UK).					
Volunteers,	Patients	and	Setting	Healthy	volunteers	were	recruited	from	University	of	Edinburgh	staff,	to	act	as	a	reference	group	for	the	cellular	markers	examined.			The	clinical	study	took	place	in	an	18-bed	teaching	hospital	medical-surgical	ICU.		Critically	ill	patients,	defined	as	those	admitted	to	ICU	and	requiring	support	of	one	or	more	organ	systems	(invasive	ventilation;	requirement	for	vasopressors	and/or	inotropes;	or	haemofiltration)	and	predicted	to	require	such	support	for	48	hours	or	more,	were	screened	for	recruitment.		Exclusion	criteria	were:	age	<16;	pregnancy;	known	human	immunodeficiency	virus	(HIV)	infection;	known	
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in-born	errors	of	neutrophil	metabolism;	hematological	malignancy;	use	of	immunosuppressive	drugs	other	than	corticosteroids;	and	those	thought	unlikely	to	survive	for	more	than	24	hours.	Patients	were	also	excluded	if	they	were	involved	in	another	study	that	involved	blood	sampling,	or	if	they	had	suspected	H1N1	influenza.			Informed	consent	was	obtained	directly	from	patients	where	possible,	otherwise	informed	consent	was	obtained	from	the	next	of	kin.		Clinical	data	were	collected	regarding	potential	risk	factors	for	nosocomial	infection	15,	these	data	included	‘shock’,	defined	by	requirement	for	noradrenaline,	adrenaline	and/or	dobutamine	infusion.		EDTA	anti-coagulated	blood	was	collected	at	study	enrolment	(within	48	hours	of	ICU	admission),	then	at	study	day	2,	days	3-4	and	days	6-10	unless	a	study	end-point	was	achieved.		Study	end-points	were	-	ICU-acquired	infection	(see	Supplementary	Section	for	definition);	death	without	ICU-acquired	infection;	or	discharge	from	ICU	without	ICU-acquired	infection.			Details	of	flow	cytometric	protocols	and	analysis	for	determination	of	immune	dysfunction	are	included	in	the	supplemental	section.	
	
Infections	Diagnostic	criteria	were	pre-defined	for	the	major	ICU-acquired	infections,	namely	ventilator-associated	pneumonia	(VAP),	blood	stream	infection	(BSI),	vascular	catheter-related	infection	(CRI),	urinary	tract	infection	(UTI)	and	surgical	site/soft	tissue	infections,	based	on	those	from	the	HELICS	programme21	(see	supplemental	section	for	details).	Data	on	infections	were	recorded	by	the	study	nurses	(JA	and	CM),	who	were	blinded	to	the	immune	phenotype.		Day	of	
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infection	was	defined	as	the	day	on	which	positive	microbial	culture	was	obtained	from	the	patient.				Where	infection	was	strongly	clinically	suspected	but	did	not	fulfil	HELICS	criteria	(for	instance	when	cultures	were	taken	whilst	on	antibiotics	and/or	cultures	were	negative/equivocal),	an	expert	panel	(IFL,	AWH,	DGS,	TSW	and	AJS),	blinded	to	the	immune	phenotype,	reviewed	patients’	data	and	the	presence	or	absence	of	infection	was	adjudicated.	In	the	absence	of	positive	cultures	the	day	of	infection	was	defined	as	the	day	of	clinical	deterioration.			The	adjudication	outcome	could	be	‘confirmed’,	‘probable’	or	‘unlikely’	infection.		Details	of	diagnostic	criteria	and	expert	panel	adjudication	procedures	are	set	out	in	the	Supplementary	Section.			
Statistical	analysis	Analysis	was	conducted	using	Prism	(Graphpad	Software,	La	Jolla,	CA,	USA)	and	PASW	Statistics	Version	18	(IBM	Corp,	Armonk,	NY,	USA).			Contingency	tables	were	analyzed	by	Fisher’s	exact	test	(for	2x2)	and	chi-squared	(for	>2x2).	Continuous	data	that	were	not	normally	distributed	were	log-transformed	to	normality	to	permit	parametric	analysis,	with	one	way	or	two	way	ANOVA	used	as	appropriate.	A	Cox	hazards	model	was	constructed	to	examine	the	effects	of	immune	dysfunctions	and	other	clinical	variables	on	acquisition	of	infection	over	time.			Variables	for	inclusion	in	the	final	Cox	model	
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were	selected	by	step-wise	conditional	entry	with	a	threshold	of	P≤0.05.		P≤0.05	was	considered	statistically	significant.		
	
Ethical	approval	Written	informed	consent	was	obtained	from	the	patient,	or	where	incapacitated	from	their	nearest	relative.		The	study	was	approved	by	the	Scotland	A	Research	Ethics	committee	(study	number	09/MRE00/19).				Healthy	volunteers	provided	written	informed	consent,	and	their	involvement	was	approved	by	Lothian	Research	Ethics	committee	(study	number	08/S1103/38).		Data	relating	to	C5a-mediated	dysfunction	in	the	first	60	patients	described	here	have	been	published	elsewhere	in	a	paper	delineating	the	mechanisms	of	C5a-dependent	impairment	of	neutrophil	phagocytosis	and	its	clinical	relevance	8.		
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Results		
Recruitment	Ninety-six	patients	were	recruited.	Blood	samples	were	missing	for	one	patient	and	so	95	entered	the	final	analysis.	42	(44%)	patients	were	admitted	with	sepsis,	9	of	whom	had	acquired	their	infection	in	hospital	prior	to	ICU	admission.		Details	of	sites	and	organisms	involved	are	shown	in	Tables	S1	and	S2	in	the	supplemental	section.	
	
Infections	Thirty-three	patients	(35%)	developed	nosocomial	infection	whilst	in	ICU	(26	confirmed	infections	and	7	probable).		Details	of	the	sites	of	infections	are	shown	in	Table	1,	infecting	organisms	are	shown	in	Table	2.	The	median	length	of	stay	before	developing	infection	was	6	days	(IQR	5-7	days).		In	total	20	patients	underwent	adjudication	panel	review,	5	were	ruled	‘confirmed’,	7	‘probable’	and	8	‘unlikely’.			Further	details	of	adjudications	can	be	found	in	the	supplemental	section.	Amongst	the	patients	admitted	with	sepsis,	who	subsequently	developed	ICU-acquired	infection,	the	organisms	differed	in	every	case	and	in	all	but	one	case	the	site	of	the	new	infection	was	different	(the	exception	being	a	patient	admitted	with	Bronchoalveolar	lavage	PCR-positive	Varicella	pneumonitis	who	subsequently	developed	Gram	negative	bacterial	VAP).	
	22	(23%)	of	patients	died	during	their	ICU	admission,	11	(50%)	were	judged	to	have	died	of	a	septic	insult,	including	5	with	an	admission	diagnosis	of	sepsis	and	6	who	developed	secondary	sepsis	from	an	ICU-acquired	infection.	
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	Details	of	total	and	differential	white	cell	counts	at	each	time	point	are	shown	in	the	supplemental	section	(figure	S2).		
Regulatory	T-cells	The	percentage	of	Tregs	at	the	various	time	points	after	study	entry,	compared	to	healthy	donors	Treg	levels,	were	higher	than	those	seen	in	healthy	donors	(p=0.018	by	ANOVA,	data	not	shown).		When	divided	into	patients	developing	nosocomial	infection	in	the	ICU	and	those	not,	Tregs	were	significantly	higher	amongst	patients	developing	infection	(p=0.012)	(Figure	1A).		
	
Monocyte	deactivation	The	expression	of	monocyte	surface	HLA-DR	was	significantly	suppressed	relative	to	healthy	volunteers	(P<0.0001	by	ANOVA	data	not	shown).		Patients	developing	nosocomial	infections	had	significantly	lower	levels	of	monocyte	HLA-DR	than	those	who	did	not	(p=0.018)	(Figure	1B).		
Complement	mediated	neutrophil	dysfunction	Significantly	depressed	levels	of	neutrophil	CD88	were	found	in	patients,	relative	to	healthy	donors	(P<0.001	by	ANOVA,		data	not	shown).		Again	patients	who	subsequently	developed	nosocomial	infection	displayed	lower	levels	of	CD88,	implying	greater	levels	of	C5a	exposure	(p=0.001)	(Figure	1C).		In	keeping	with	our	previous	work	showing	the	specific	association	between	CD88	expression	and	neutrophil	dysfunction		6,8,	no	association	was	found	between	nosocomial	
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infection	and	other	markers	of	neutrophil	activation	(CD11b,	CD64	and	L-selectin,	data	not	shown),	suggesting	that	the	effect	seen	is	not	reflective	of	generic	activation.		This	is	in	contrast	to	other	work	suggesting	a	diagnostic	role	for	CD11b	and	CD64	for	infection22	,	however	we	examined	the	ability	of	markers	to	predict	future	infection	rather	than	diagnose	it	after	it	had	occurred.		
Examining	the	cut-off	for	dysfunction	by	relationship	to	infection	At	the	planned	interim	analysis	8,	the	optimal	cut-points	were	examined	using	ROC	curves	and	Youden’s	index	23;	this	revealed	an	optimal	cut-point	of	9.8%	for	Tregs,	10,000	molecules	per	cell	for	HLA-DR	and	a	geometric	mean	fluorescence	of	246	for	CD88.		Thirty-seven	patients	had	Treg	levels	>9.8%	prior	to	achieving	a	study	endpoint	(i.e.	ICU-acquired	infection,	death	without	infection	or	discharge	without	infection),	the	majority	of	whom	(26,	70%)	had	normal	levels	on	study	admission.		The	remaining	58	patients	had	levels	below	9.8%,	although	in	8	(14%)	of	them	levels	had	started	>9.8%	and	fallen	prior	to	study	endpoint.		As	noted	above,	in	patients	acquiring	infection	in	ICU,	data	were	censored	for	two	days	prior	to	infection	for	purposes	of	classifying	Treg	status.		This	changeability	in	Treg	status	led	us	to	analyse	this	as	a	time-dependent	variable	in	the	Cox	hazard	analysis	(see	below).		Of	note	many	patients	showed	evidence	of	increased	CD25	positive	lymphocytes,	a	known	marker	of	lymphocyte	activation	
24,	reinforcing	the	need	for	FOXP3	staining	in	addition	to	cell	surface	markers	of	regulatory	status	20.	
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62	patients	had	monocyte	dysfunction	whilst	69	had	neutrophil	dysfunction.	In	contrast	to	the	Tregs,	patients	were	far	less	likely	to	change	from	‘dysfunction’	to	‘no	dysfunction’	(or	vice	versa)	with	respect	to	monocyte	HLA-DR	and	neutrophil	CD88	expression.	75%	of	patients	remained	in	the	same	monocyte	group	as	their	admission	sample,	whilst	13%	progressed	from	‘no	dysfunction’	to	‘dysfunction’	and	14%	went	in	the	opposite	direction.		Of	the	minority	who	changed	groups,	all	but	2	were	in	their	eventual	group	by	day	3	post-admission.	Regarding	neutrophil	groups	84%	of	patients	remained	in	the	same	group	as	their	admission	sample,	whilst	13%	progressed	from	‘no	dysfunction’	to	‘dysfunction’	and	3%	went	in	the	opposite	direction.		Of	the	minority	who	changed	groups,	all	but	3	were	in	their	eventual	group	by	day	3	post-admission.	
	
	
	
Effect	of	dysfunction	on	acquisition	of	infection	Those	patients	whose	Tregs	were	above	9.8%	had	an	increased	risk	of	acquiring	nosocomial	infection,	with	a	relative	risk	increase	of	2.4	(95%CI	1.3-4.2,	p=0.002	by	Fisher’s	exact	test).			Monocyte	deactivation,	at	the	cut-off	of	10,	000,	was	associated	with	a	significantly	increased	risk	of	infection;	relative	risk	of	3	(95%CI	1.3-6.9,	p=0.0035	by	Fisher’s	exact	test).		C5a-mediated	neutrophil	dysfunction	was	also	associated	with	an	increased	relative	risk	of	4.7,	(95%	CI	1.2-18.3,	P=0.007	by	Fisher’s	exact	test).		In	sensitivity	analyses	all	three	measures	retained	their	significant	values	when	‘probable’	infections	were	excluded,	as	well	as	when	urinary	tract	infections	were	excluded	(data	not	shown).	
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	Using	these	same	cut-offs	to	examine	other	outcomes	(all	cause	mortality	and	death	from	sepsis),	none	of	the	measures	showed	significant	association	with	all-cause	death	(Tregs	p=0.79,	monocyte	deactivation	p=0.42	and	neutrophil	dysfunction	p=0.2,	all	analyses	by	Fisher’s	exact	test).		When	examining	death	from	sepsis,	only	neutrophil	dysfunction	was	significantly	associated	(p=0.03	by	Fisher’s	exact	test,	Tregs	p=0.09	and	monocyte	deactivation	p=0.32).					
	
Evaluation	of	the	impact	of	other	clinical	variables	on	acquisition	of	infection	As	an	exploratory	analysis	data	concerning	demographic	and	clinical	factors	previously	associated	with	nosocomial	infection	15	were	entered	into	a	Cox	hazards	model,	in	a	conditional	stepwise	approach	using	a	threshold	of	p≤0.05		(Table	3).	Elevated	Tregs	were	treated	as	a	time-dependent	co-variate	as	this	measure	showed	considerable	variability	over	time.		In	this	model	both	Tregs	and	neutrophil	dysfunction	retained	their	significant	association	(Table	4),	however	monocyte	deactivation	became	non-significant	(p=0.29)	and	was	excluded	from	the	final	model.			The	only	clinical	predictor	found	to	be	significant	was	blood	transfusion,	which	was	associated	with	a	lower	risk	of	nosocomial	infection.		The	overall	model	and	hazard	ratio	estimates	for	the	predictor	variables	are	shown	in	table	4.		An	alternative	method	of	variable	selection	for	the	Cox	model,	using	univariate	regression	resulted	in	Tregs	and	neutrophil	dysfunction	remaining	significant	at	p=0.05	but	again	monocyte	deactivation	lost	significance	(Tables	S3	and	4,	supplemental	section).	
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	Finally	the	effect	of	cumulative	occurrence	of	immune	dysfunction	was	analyzed.	Patients	were	analyzed	by	whether	they	had	0,1,2	or	3	dysfunctions	(Table	5).	This	demonstrated	an	incremental	risk	of	nosocomial	infection	with	accumulating	immune	dysfunctions,	ranging	from	none	in	those	patients	without	immune	dysfunctions	to	75%	of	those	who	had	all	three	(P=0.0004	by	Chi2	test	for	trend).			Cumulative	immune	dysfunction	did	not	predict	all	cause	mortality	(p=0.25	by	Chi2	test	for	trend),	but	was	highly	significant	when	looking	at	deaths	from	sepsis	(p=0.0072	Chi2	test	for	trend).		
Effect	of	infection	on	dysfunction	To	examine	whether	the	development	of	ICU-acquired	infection	altered	the	measures	of	dysfunction,	samples	from	time	points	before	and	after	ICU-acquired	infection	were	examined	(Figure	2A-C)	and	demonstrated	no	significant	change	across	the	time	intervals	examined.		Analysis	of	the	measures	of	dysfunction	in	the	first	samples	taken	from	patients	with	and	without	infection	on	admission	revealed	no	significant	difference	between	these	two	groups	(%	Tregs	p=0.41	HLA-DR	p=0.49	CD88	p=0.73,	by	t-test	on	log	transformed	data).		
	
Discussion	
 This	study	demonstrates	the	temporal	course	of	three	measures	of	immune	dysfunction	amongst	critically	ill	patients,	illustrating	that	immune	dysfunction	is	not	an	‘all	or	nothing’	response	and	can	affect	different	cell	types	at	different	
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times.		Although	the	magnitude	of	immune	dysfunction	appears	to	worsen	as	the	critical	illness	progresses,	in	many	cases	patients	demonstrate	dysfunction	early	on	(i.e.	within	48	hours	of	ICU	admission).		Interestingly	this	study	does	not	support	the	recent	suggestion	that	immune	dysfunction	is	restricted	to	patients	with	sepsis	12,	as	we	found	evidence	of	dysfunction	amongst	patients	with	both	sterile	and	infective	causes	of	critical	illness.		This	study	demonstrates,	for	the	first	time,	an	association	between	elevated	Tregs	and	the	acquisition	of	nosocomial	infection.		The	association	with	infection	is	also	extended	to	diminished	neutrophil	CD88	expression,	and	both	compare	well	to	the	more	established	marker,	reduced	monocyte	HLA-DR	9.			This	study	involved	assessment	of	several	distinct	mechanisms	of	immune	dysfunction,	and	allowed	for	dynamic	changes	in	immune	cell	function	rather	than	relying	on	a	single	time	point.	Immunophenotyping	in	critical	illness	is	a	relatively	new	field,	and	determining	what	constitutes	‘immune	dysfunction’	and	how	this	could	be	determined	by	quantifying	cell	surface	markers	remains	uncertain.		This	study,	whilst	exploratory	in	nature,	has	derived	two	potential	new	markers	for	susceptibility	to	nosocomial	infection	alongside	a	more	established	marker.					It	is	interesting	that	the	cut-offs	determined	by	examining	patients	with	and	without	nosocomial	infection	were	close	to	those	suggested	by	more	mechanistic	work.		A	cut-off	of	10%	of	CD4	cells	was	suggested	as	an	indicator	of	inappropriately	elevated	Tregs	in	a	recent	study	14,	very	close	to	our	value	of	
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9.8%.		Similarly	the	cut-off	for	CD88	of	246	arbitrary	fluorescence	units	is	close	to	the	value	of	250	which	in	our	hands	corresponded	to	50%	of	neutrophils	capable	of	efficient	phagocytosis	of	zymosan	in	patients	8.	The	cut	off	described	here	is	also	close	to	the	value	we	observed	when	healthy	volunteer	neutrophils	were	exposed	to	10nM	C5a	8	which	is	well	within	the	concentration	range	seen	in	severe	sepsis	25.		Our	cut-off	for	HLA-DR	was	higher	than	that	described	in	previous	studies	9	although	the	previous	measure	was	looking	at	risk	of	death	rather	than	development	of	nosocomial	infection.			The	infections	had	to	meet	rigorous,	reproducible	criteria	and	any	cases	not	meeting	these	criteria	underwent	review	by	experts	blinded	to	the	immune	cell	data.	Urinary	tract	infections	(UTI)	can	be	difficult	to	discern	in	critically	ill	patients,	given	the	risk	of	bladder	colonisation	with	catheterisation	26.	However	those	patients	acquiring	UTI	had	no	clinical	or	microbiological	evidence	of	infection	from	other	sites	and	all	exceeded	the	rigorous	microbiological	criteria	set	before	the	study	(i.e.	all	UTIs	were	single	organisms	grown	at	high	concentrations	of	>106	CFU	ml-1).		Encouragingly,	excluding	UTIs	or	infections	only	judged	‘probable’	did	not	significantly	reduce	the	predictive	ability	of	our	immune	markers.		These	findings	will,	however,		require	further	confirmation	in	an	independent	validation	data	set.		As	with	any	observational	study	we	cannot	be	certain	that	the	observed	associations	are	causative,	however	we	took	steps	to	minimize	the	risk	of	picking	up	epiphenomenal	changes	associated	with	infection.		Indeed,	analysis	of	the	measures	before	and	after	the	acquisition	of	infection	did	not	support	a	simple,	
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epiphenomenal	relationship.	Furthermore,	it	is	biologically	plausible	that	immune	dysfunction	is	causally	linked	to	the	acquisition	of	nosocomial	infection.		Although	we	cannot	rule	out	the	effect	of	residual	confounding	from	unmeasured	variables,	we	have	accounted	for	many	of	the	risk	factors	previously	mooted	for	nosocomial	infection	15.		Several	studies	have	demonstrated	elevated	levels	of	Tregs	in	patients	with	sepsis	13,	14,	and	recent	animal	and	in	vitro	work	has	shown	Tregs	mediating	impaired	T-cell	proliferative	responses	in	this	disease	14.		The	current	study	extends	the	findings	of	elevated	Tregs	to	critically	ill	patients	without	sepsis,	suggesting	that	their	elevation	is	part	of	a	stereotyped	response	to	systemic	inflammation	rather	than	a	specific	response	to	severe	infection.			Although	the	association	between	elevated	Tregs	and	adverse	outcomes	is	consistent	with	some	previous	work	14,	this	finding	is	by	no	means	universal	with	other	studies	showing	no	effect	27,	or	even	protective	effects	in	animal	models28.	It	is	also	interesting	to	note	the	generally	increased	expression	of	CD25	noted	on	CD4	cells	from	critically	ill	patients,	reflecting	the	nature	of	CD25	as	a	marker	of	lymphocyte	activation	24	and	emphasising	the	need	for	additional	measures	such	as	FOXP3	for	identifying	Tregs	in	this	patient	population.			The	field	of	regulatory	T-cell	identification	is	developing	rapidly,	and	additional	measures	beyond	those	used	in	this	study	may	further	improve	the	predictive	ability	and	add	new	information	regarding	expression	of	sub-sets	of	regulatory	T-cells	in	critical	illness	29.		Indeed	use	of	CD127	negativity	14	as	a	marker	would	eliminate	a	step	of	the	current	process	and	produce	a	more	rapidly	available	result,	however	these	developments	would	require	validation	in	a	further	study.	
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	Although	the	finding	of	monocyte	deactivation,	and	low	HLA-DR	expression,	predicting	nosocomial	infection	is	not	a	new	one	30,	31	the	finding	is	not	universally	consistent	32.			The	role	of	excessive	complement	activation	in	the	pathogenesis	of	sepsis	and	non-septic	critical	illness	is	increasingly	recognised	
33,34.		Animal	models	of	sepsis	and	trauma,	and	patient	studies,	have	demonstrated	C5a-mediated	neutrophil	dysfunction	6-8,	33-35.			To	our	knowledge	this	is	the	first	study	to	examine	several	different	cellular	markers	of	immune	dysfunction	simultaneously	at	multiple	time	points,	and	to	demonstrate	a	cumulative	effect	when	it	comes	to	predicting	nosocomial	infection.		It	remains	a	distinct	possibility	that	the	effects	are	not	simply	additive,	but	may	indeed	be	synergistic.	There	is	evidence	of	neutrophil	subsets	suppressing	lymphocyte	functions36	and	regulatory	T-cells	inhibiting	neutrophil	functions37.		The	current	study	was	not	designed	to	answer	such	questions,	however	investigation	of	potential	interactions	is	the	subject	of	ongoing	studies.		It	is	interesting	to	speculate	why	our	study	did	not	show	significant	effects	of	many	of	the	demographic	and	clinical	factors	that	have	been	previously	linked	to	nosocomial	infection	15.	It	is	important	to	note	that	although	there	are	a	variety	of	acknowledged	risk	factors	-	including	severity	of	illness,	intubation,	total	parenteral	nutrition	and	tracheostomy	38-44		–	there	is	relatively	low	concordance	between	studies,	which	often	yielded	different	combinations	of	factors	38,	42-44.	Furthermore	many	studies	do	not	adequately	account	for	the	relationship	between	interventions	such	as	tracheostomy,	or		total	parenteral	nutrition	and	
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length	of	stay	(i.e.	duration	of	risk	exposure),	in	that	the	longer	a	patient	remains	in	ICU	the	more	likely	they	are	to	receive	one	of	these	interventions	41,43,	with	the	added	confounder	that	those	acquiring	nosocomial	infection	tend	to	stay	in	ICU	longer	42.	Many	epidemiological	studies	of	infection	in	ICU	include	all-comers,	whereas	in	this	study	we	deliberately	recruited	a	group	who	were	thought	to	be	at	high	risk.		All	our	patients	had	some	form	of	invasive	device	in	place,	be	it	an	endotracheal	tube,	central	venous	catheter	or	haemofiltration	line,	to	facilitate	the	organ	support	that	was	an	entry	criterion.		With	a	median	APACHE	II	of	22	(IQR	18-28),	these	patients	were	a	sicker	subset	of	all	ITU	patients	admitted	to	our	unit.			The	apparent	‘protective’	effect	of	blood	transfusion	was	an	unexpected	finding,	as	previous	studies	have	suggested	it	as	a	risk	factor	for	infection43.	This	could	be	a	genuine	effect	resulting	from	hetrologous	blood’s	immunostimulatory	effects45,	or	it	may	relate	to	failure	to	correct	for	unmeasured	confounders.		
 
	
Conclusions	This	study	has	added	new	knowledge	regarding	the	timing	and	magnitude	of	immune	dysfunction	occurring	in	critically	ill	adults,	and	related	these	findings	to	an	important	clinical	outcome,	namely	the	development	of	nosocomial	infection.		We	have	shown	that	these	effects	are	not	restricted	to	patients	with	sepsis	but	occur	in	those	with	sterile	insults	as	well.		We	have	also	demonstrated	
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the	utility	of	blood	cell-based	markers	of	immune	dysfunction	and	thus	set	the	scene	for	future	validation	and	intervention	trials.		
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Figure	legends		
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Figure	1.	Measures	of	immune	dysfunction	by	subsequent	infection	status	Panel	A:	T-regs	as	a	percentage	of	all	CD4+	TH	cells.	p=0.012	for	difference	between	outcomes,	p=0.025	for	difference	over	time	by	two	way		ANOVA.	Panel	B:	Monocyte	HLA-DR	expression.	p=0.018	for	difference	between	outcomes,	p=0.56	for	difference	over	time	by	two	way		ANOVA.	Panel	C:	Neutrophil	CD88	expression	p=0.0034	for	difference	between	outcomes,	p=0.001	for	difference	over	time	by	two	way		ANOVA.	Data	shown	as	mean	and	95%	confidence	intervals.	Analyses	performed	on	log-transformed	data.	PE,	phycoerythrin;	geoMCF,	geometric	mean	cell	fluorescence.
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Figure	2.	Changes	in	measures	of	immune	dysfunction	before	and	after	ICU-
acquired	infection	(n=33).	
	Panel	A:	Tregs	as	a	percentage	of	all	CD4+ve	lymphocytes,	p=0.28	by	ANOVA.	
Panel	B:	Monocyte	HLA-DR	expression,	p=0.56	by	ANOVA.	
Panel	C:	Neutrophil	CD88	expression,		p=0.95	by	ANOVA.	
	All	data	shown	as	mean	and	95%	CI,	all	analyses	performed	on	log-transformed	data.	Hatched	line	indicates	the	‘cut-off’	for	immune	dysfunction.	PE,	phycoerythrin;	geoMCF,	geometric	mean	cell	fluorescence.		 													
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	Confirmed	infections	 		 Pneumonia-10		(7	VAP)	Blood	stream	infections-4	Catheter-related	blood	stream	infections-3	Urinary	tract	infections-5	Surgical	site/soft	tissue	infections-4	Probable	infections	 		 Pneumonia-4	(all	VAP)	Intra-abdominal	infection-3		
Table	1.	Site	of	infections	acquired	in	ICU.	
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Infection	category	 Organism	 Frequency	
Confirmed	 Staphylococcus	aureus	 3	
	 Coagulase	negative	
Staphylococci	
1	
Streptococcus	
pneumoniae	
1	Other	Streptococci	 1	
Enterococcus	faecalis	 2	
Burkholderia	cepacia	 1	
Citrobacter	braakii	 1	Coliform	–no	further	specification	 1	
Enterobacter	cloacae	 3	
Escherichia	coli	 5	
Klebsiella	pneumoniae	 2	
Haemophilus	influenzae	 1	
Pseudomonas	aeruginosa	 3	Anaerobes	 1	
Candida	albicans	 4	
Herpes	simplex	 1	
Probable	 Staphylococcus	aureus	 1	
	 Culture	negative		 4	No	samples	taken	as	care	withdrawn	 2	
Unlikely	 Staphylococcus	aureus	 2	
	 Coagulase	negative	
Staphylococci	 2	
Streptococcus	
pneumoniae	
1	
Acinetobacter	baumannii	 1	
Haemophilus	influenzae	 1	
Klebsiella	pneumoniae	 1	
Candida	albicans	 1	Culture	negative	 2	
	
Table	2.	Culture	results	from	patients	with	confirmed,	suspected	and	
unlikely	infections.			More	than	one	organism	was	isolated	from	some	patients.				
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		 Variable	 Infection	 No	infection	 P	value	for	Cox	hazards	analysis	Pre-morbid	factors	 Number	of	co-morbid	conditions	by	Charlson	index,	median	(IQR)		
3	(1.5-4)	 3	(1-5)	 0.08	
%	with	chronic	lung	disease	 19%	 9%	 0.62	%	with	diabetes	mellitus	 18%	 19%	 0.36	Age,	median	(range)	 60	(20-88)	 59	(16-85)	 0.34	%	male	 61%	 63%	 0.06	Admission	factors	 Admission	SOFA	score,	median	(IQR)	 9	(6.5-11)	 8	(4-10)	 0.11	Admission	APACHE	II	Score,	median	(IQR)	 21	(18-26)	 23.5(18.5-29)	 0.26	%	fulfilling	criteria	for	shock	on	admission	 76%	 56%	 0.28	%	admitted	following	surgery	 30%	 23%	 0.33	%	admitted	following	trauma	 1%	 5%	 0.79	Illness	course/interventions	prior	to	endpoint	achievement	
Peak	SOFA	score,	median	(IQR)	 9	(8-12.5)	 8	(5-11)	 0.29	%	intubated	 94%	 88%	 0.22	%	with	central	venous	catheter	 90%	 88%	 0.19	%	receiving	renal	replacement	therapy	 42%	 33%	 0.23	%	with	tracheostomy	 8%	 6%	 0.30	%	with	urinary	catheter	 92%	 97%	 0.30	%	receiving	H2	 100%	 98%	 0.70	
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antagonist/proton	pump	inhibitor	%	receiving	corticosteroids	 30%	 23%	 0.74	%	receiving	a	blood	transfusion	 52%	 44%	 0.002*	%	receiving	total	parenteral	nutrition	 27%	 18%	 0.92	Immune	profiling	 %	with	elevated	Tregs	 60%	 29%	 0.026*	%	with	low	CD88	 94%	 62%	 0.009*	%	with	low	HLA-DR	 85%	 55%	 0.29	
	
Table	3.	Demographic	and	clinical	factors	amongst	those	with	and	without	
nosocomial	infection.		Right	hand	column	indicates	p	value	for	hazard	ratios	determined	during	stepwise	conditional	evaluation,	variables	marked	*	entered	the	final	model	(see	table	4	below).				
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	Variable	 P	value	 Hazard	Ratio	(95%	CI)	Overall	model		 0.001	 NA	*Elevated	Tregs	 0.026	 2.4	(1.1-5.4)	Neutrophil	dysfunction	 0.009	 6.9	(1.6-30)	Blood	transfusion	 0.002	 0.3	(0.1-0.6)		
Table	4.	Cox	model	for	occurrence	of	nosocomial	infection.			
*Elevated	Treg	cells	were	expressed	as	a	time-dependent	co-variate.	NA	=	not	applicable.	
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Number	of	
dysfunctions	a	
N=	 %	acquiring	
nosocomial	
infection	(95%	CI)	
0	 11	 0		(0-0%)	
1	 21	 10%	(0-22%)	
2	 43	 37%	(23-52%)	
3	 20	 75%	(56-94%)		
Table	5.	Relationship	between	burden	of	immune	dysfunction	and	
acquisition	of	nosocomial	infection.		(ai.e.	neutrophil	dysfunction	(as	indicated	by	low	CD88),	monocyte	deactivation	(as	indicated	by	low	HLA-DR)	and	elevated	regulatory	T-cells).	P=0.0004	by	Chi	squared	test	for	trend.	
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Figure 1: Measures of immune dysfunction by subsequent infection status 
X axis indicates time after study enrolment (Day 0) 
Panel A: T-regs as a percentage of all CD4+ TH cells. p=0.012 for difference 
between outcomes, p=0.025 for difference over time by two way  ANOVA. 
Panel B: Monocyte HLA-DR expression. p=0.018 for difference between 
outcomes, p=0.56 for difference over time by two way  ANOVA 
Panel C: Neutrophil CD88 expression p=0.0034 for difference between 
outcomes, p=0.001 for difference over time by two way  ANOVA 
Data shown as mean and 95% confidence intervals. Analyses performed on log-
transformed data. 
A 
B 
C 
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Figure	2:Changes	in	measures	of	immune	dysfunction	before	and	after	ICU-
acquired	infection	(n=33	patients). 
	Panel	A:	Tregs	as	a	percentage	of	all	CD4+ve	lymphocytes,	p=0.28	by	ANOVA 
Panel	B:	Monocyte	HLA-DR	expression,	p=0.56	by	ANOVA 
Panel	C:	Neutrophil	CD88	expression,		p=0.95	by	ANOVA 
	All	data	shown	as	mean	and	95%	CI,	all	analyses	performed	on	log-transformed	
data.	Hatched	line	indicates	the	‘cut-off’	for	immune	dysfunction. 
		
42	
42	
Supplemental	methods	–	definition	of	infection			These	criteria	were	based	on	those	provided	by	HELICS	(main	text	reference	21).			Any	new	infection	occurring	after	48	hours	of	ICU	admission	was	deemed	‘ICU-acquired’.	For	consistency	infections	arising	within	48	hours	of	ICU	discharge	were	deemed	‘ICU-acquired’.		Infections	were	defined	prior	to	the	start	of	the	study	as	follows,	based	on	the	HELICS	criteria.		
a)	Ventilator-associated	pneumonia:  Requires	radiographic,	clinical	and	microbiological	criteria	to	be	met:		
 i.	Radiological	criteria.	CXR	or	CT	scan	showing	new	infiltrates,	or	worsening	infiltrates	without	evidence	of	pulmonary	oedema,	and	either	pyrexia	of	>38oC	or	white	cell	count	>12	x109	L	-1	or	<4x109	L-1.			These	must	be	combined	with	one	or	more	clinical	criteria.			ii.	Clinical	criteria.	
• Worsening	oxygenation	–	any	increase	in	Fi02	to	maintain	Pa02	target,	or	an	increase	in	PEEP,	frequency	or	tidal	volume,	proning	or	paralysis	to	facilitate	ventilation.		
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• Relevant	clinical	chest	findings	–	auscultatory	finding	of	crepitations,	crackles	or	decreased	air	entry.		
• Increased/changed	sputum	–	any	increase	in	volume,	presence	of	muco-purulent	or	muco-purulent-bloody	sputum.		iii.	Microbiological	criteria.	The	above	radiological	and	clinical	criteria	must	be	combined	with	positive	quantitative	BAL	culture	of	>104CFU	ml-1	or	positive	pleural	fluid	or	pulmonary/pleural	abscess	culture.	Where	the	diagnosis	of	VAP	has	been	suggested	by	mini-BAL,	endotracheal	aspirate	or	where	growth	is	below	the	104	CFU	ml-1	threshold	or	without	any	positive	microbiology,	adjudication	is	required.		
Hospital-acquired	pneumonia	(HAP),	i.e.	nosocomial	pneumonia	in	non-mechanically	ventilated	patients,	requires	the	same	fulfilment	of	criteria	as	VAP	except	that	sputum	cultures	with	heavy	growth	of	a	single	organism	constitute	a	confirmed	infection.		
b)	Catheter-associated	infections	Positive	culture	(semi-quantitative	>15CFU)	from	an	indwelling	vascular	line	combined	with	either	
• Local	inflammation	and	pus	(catheter-related	infection	(CRI))	or	
• Improvement	of	inflammatory	markers	within	48	hours	of	removal	(CRI)	or	
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• Culture	of	the	same	organism	from	a	peripheral	blood	culture	(catheter-related	blood	stream	infection	(CRBSI)).		
c)	Blood	stream	infection	One	positive	culture	of	a	typical	pathogen,	coupled	with	evidence	of	systemic	inflammation	(WCC	>12	x109	L	-1	or	<4x109	L-1,	temperature	≥	38oC).		
d)	Urinary	tract	infection	Growth	of	2	or	fewer	organisms	at	≥	105	CFU	ml-1	combined	with	evidence	of	systemic	inflammation	(WCC	>12	x109	L	-1	or	<4x109	L-1	,	temp	>38oC	or	shock	without	another	identifiable	cause).		
e)	Soft-tissue	or	surgical	site	infection	Evidence	of	pus/inflammation	at	site	of	presumed	infection	combined	with	a	positive	culture.			Suspected	infections	which	did	not	meet	these	criteria	were	referred	to	the	consensus	panel	for	adjudication.		The	panel	was	constituted	from	a	pool	of	five	experienced	doctors,	3	intensivists	(DGS,	AWH,TSWalsh),	1respiratory	physician	(AJS)	and	1	microbiologist	(IFL),	all	of	whom	had	at	least	12	years	post-qualification	experience.		Consensus	panel	members	were	asked	to	come	to	an	independent	decision	as	to	whether	an	infection	was	‘confirmed’,	‘probable’	or	‘unlikely’.	
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A	‘confirmed’	infection	was	where	the	panel	member	was	convinced	that	infection	was	present	and	would	definitely	initiate	antibiotic	treatment	and/or	pursue	source	control.		Positive	microbial	antigen	detection	(e.g.	by	Gram	film	or	PCR),	microbial	cultures	above	an	accepted	threshold	(i.e.	>104	CFU	ml-1	from	BAL	sample),	microbial	cultures	from	a	normally	sterile	site	or	serology	confirming	a	probable	pathogen	was	obligatory,	with	other	evidence	of	infection.		
A	‘probable’	infection	is	where	the	panel	member	thought	there	was,	on	the	balance	of	probabilities,	an	infection	present	and	would	consider	antibiotic	treatment	and/or	source	control	if	the	patient’s	clinical	condition	merited	it.	This	category	could	include	positive	microbial	cultures.	An	example	would	be	culture	of	a	classically	non-pathological	organism	(e.g.	single	cultures	of	coagulase	negative	cocci	or	diphtheroids)	associated	with	clinical	evidence	of	infection/systemic	inflammation.				
An	‘unlikely’	infection	is	where	the	panel	member	thought	there	was	a	low	probability	of	infection	and	would	not	consider	antibiotic	treatment	and/or	source	control.		Although	positive	microbial	cultures	could	be	included	in	this,	this	would	be	culture	of	a	classically	non-pathological	organism		(e.g.	single	cultures	of	coagulase	negative	cocci	or	diphtheroids)	without	evidence	of	systemic	inflammation/infection	or	mixed	growth	of	commensal	organisms.		Systemic	evidence	of	infection	would	require	the	presence	of	SIRS	–	specifically	2	or	more	of	the	following:	heart	rate>90	beats	per	minute,	WCC>12	x109	L-1	or	<4	
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x109	L-1,	respiratory	rate	>20	breaths	per	minute,	or	mechanical	ventilation	and	temperature	of	>38°C	or	<36°C.		Additional	evidence	to	consider	would	include	reports	of	large	numbers	of	neutrophils	on	sample	microscopy,	and	clinical	examination	findings	of	pus	or	inflamed	tissue.		‘Unlikely’	infection	combined	with	a	positive	microbial	culture	would	constitute	colonization.		
The	consensus	panel	was	constituted	by	two	members	drawn	from	the	pool,	and	asked	to	arrive	at	an	independent	opinion	in	one	of	the	three	categories	above.		Where	there	was	agreement	the	verdict	stood,	where	there	was	disagreement	the	panel	members	met	to	try	and	agree	a	consensus	view.		If	this	failed	a	third	member	was	drawn	from	the	pool	and	asked	to	make	an	opinion	between	the	two	options	selected	by	the	initial	panel	members.		
Flow	cytometry	strategy	Flow	cytometry	was	conducted	on	whole	blood/EDTA	samples.		Neutrophils,	monocytes	and	lymphocytes	were	identified	by	their	size	and	granularity	(forward	and	side	scatter	respectively)	characteristics	with	confirmation	that	these	populations	were	predominantly	CD16hi	(neutrophils),	CD14hi(monocytes)	and	CD3pos	(lymphocytes).	Tregs	were	identified	by	CD4,	CD25,	FOXP3	positivity	(main	text	reference	20),	using	the	manufacturer’s	instructions	for	staining	and	permeabilisation,	and	expressed	as	a	percentage	of	total	CD4	(Thelper)	lymphocytes.			The	flow	cytometer	(FACSCalibur,	BD	Bioscience,	Oxford,	UK)	was	calibrated	weekly	using	caliBRITEtm	beads	(3	colour	and	APC,	BD	Biosciences),	linearity	and	
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sensitivity	by	8	peak	beads	(Spherotech,	Lake	Forrest,	IL,	USA).		QuantiBRITEtm	beads	(BD	Bioscience)	were	run	for	quantification	of	HLA-DR-PE	expression	(see	supplemental	section,	Figure	S1).	
	
Analysis	plan	and	immune	dysfunction		To	allow	cellular	analysis	to	be	dichotomised	into	‘dysfunction’	or	‘no	dysfunction’,	the	cut-off	points	for	percentage	of	Tregs,	monocyte	HLA-DR	and	CD88	were	examined	in	a	planned	interim	analysis	at	60	patients	(main	text	reference	8)	.		This	analysis	was	performed	by	constructing	receiver	operator	characteristic	(ROC)	curves	comparing	the	sample	most	temporally	related	to	infection	(censored	for	two	days	prior)	with	samples	from	patients	who	did	not	develop	infection,	using	Youden’s	method	(main	text	reference	23)		to	determine	the	optimal	cut-off.			Patients	were	categorized	by	the	sample	taken	most	proximally	to	an	end-point	(death,	infection,	or	discharge	without	infection)	although	in	the	case	of	those	acquiring	infection	dysfunction	was	censored	for	2	days	prior	to	the	diagnosis	of	infection	in	order	to	reduce	the	risk	that	observed	dysfunction	levels	might	reflect	the	presence	of	new	infection.		Patients	were	also	analyzed	to	determine	whether	their	immune	dysfunction	status	changed	during	admission.	
				
	
	
Supplemental	results	
	
Detail	regarding	adjudication	panel	results	
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	Of	the	non-confirmed	adjudications,	6	of	the	7	‘probable’	infections	had	either	negative	cultures	whilst	on	antibiotics,	with	other	strong	clinical	evidence	of	infection	or	did	not	have	cultures	taken	as	care	was	being	withdrawn	but	with	strong	clinical	evidence.		The	remaining	‘probable’	patient	grew	bacteria	below	the	104	colony	forming	units	per	ml	cut	off	for	quantitative	culture	of	bronchoalveolar	lavage	fluid.		Of	the	‘unlikely’	infections,	two	had	negative	cultures	with	no	potential	focus	of	infection	identified,	5	had	positive	cultures	without	any	evidence	of	infection	(and	were	classified	as	‘colonisation’)	and	1	had	persistence	of	the	same	organism	cultured	on	admission	with	a	change	in	antibiotic	sensitivities.		
Leucocyte	counts	in	patients	Patients	had	elevated	total	white	cell	counts	on	admission	(mean	14.1	x109	L-1,	95%	CI	12.4-15.9	x109	L-1,	normal	range	(NR)	4.0-12.0	x109	L-1).	Neutrophil	counts	were	also	elevated	(mean	11.8	x109	L-1,	95%	CI	10.2-13.4,	NR	2-7.5	x109	L-1).		Lymphocyte	counts	were	suppressed	(mean	1.1	x109	L-1,	95%	CI	0.9-1.2	x109	L-1,	NR	1.5-4	x109	L-1),	whilst	mean	monocyte	counts	were	within	the	normal	range	(mean	0.7	x109	L-1,		95%	CI,	0.6-0.9	x109	L-1,	0.2-0.8	NR	x109	L-1).		When	stratified	by	patients	subsequently	developing	infection	or	not,	total	white	cell	count	was	significantly	more	elevated	in	patients	developing	infection,	with	this	effect	persisting	when	samples	were	censored	for	two	days	prior	to	infection.	The	increased	white	cell	count	was	mostly	due	to	neutrophilia	(see	Figure	S2A	and	B).		By	contrast	lymphocyte	and	monocyte	numbers	didn’t	differ	
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between	the	groups,	although	both	showed	significant	rises	over	time	(Figure	S2C	and	D).	
	
	
	
	
Data	relating	to	patients	who	had	evidence	of	infection	prior	to	admission	
to	ICU	
	The	relevant	site	of	infection	is	described	in	Table	S1,	and	the	range	of	organisms	isolated	in	Table	S2.		
Alternative	modelling	for	effects	of	immune	dysfunctions	and	other	clinical	
variables	on	acquisition	of	infection	over	time.		An	alternative	model	to	that	described	in	Tables	3	and	4	of	the	main	manuscript	was	employed.	The	alternative	model	used	univariate	regression	analysis	and	entering	variables	with	a	p	value	of	≤0.1.	Low	CD88	expression	and	elevated	Tregs	retained	significance	in	this	model	(Tables	S3	and	S4).		
Calibration	of	flow	cytometer	Example	data	from	the	QuantiBRITE	beads	from	two	calibration	runs	are	shown	in	figure	S1.		
	
	
Changes	in	differential	leucocyte	count	
		
50	
50	
Changes	in	total	leucocyte	and	differential	counts	over	time,	dichotomised	by	infection	outcome,	are	shown	in	figure	S2.		
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Source	of	Sepsis	 Number	of	patients	 Number	hospital-
acquired	
Pneumonia		 17	 6	
Intra-abdominal	
collection	
8	 1	
Pelvic	collection	 1	 0	
Urinary	tract	 4	 1	
Soft	tissue	infection	 5	 0	
Central	nervous	system	 2	 0	
Blood	stream	(no	other	
source	identified)	
4	 1	
Endocarditis	 1	 0	
	
Table	S1.	Source	of	sepsis	present	at	admission	to	ICU.				
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	Organism	 N	
Staphylococcus	aureus	 6	Group	A	Streptococcus	 3	
Haemophilus	influenzae	 3	
Escherichia	coli	 9	
Citrobacter	braakii	 1	
Enterobacter	aerogenes	 1	
Acinetobacter	baumannii	 1	
Candida	albicans	 2	Enterovirus	 1	
Varicella	zoster	 1	Influenza	virus	A	 1	Parainfluenza	virus	 1	Culture	negative	 15			
Table	S2.	Organisms	cultured	from	patients	admitted	to	ICU	with	sepsis.	Some	patients	had	more	than	one	organism	isolated.	
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		 Variable	 Infection	 No	infection	 P	value	for	univariate	analysis	Pre-morbid	factors	 Number	of	co-morbid	conditions	by	Charlson	index,	median	(IQR)		
3	(1.5-4)	 3	(1-5)	 0.44	
%	with	chronic	lung	disease	 19%	 9%	 0.2	%	with	diabetes	mellitus	 18%	 19%	 0.89	Age,	median	(range)	 60	(20-88)	 59	(16-85)	 0.88	%	male	 61%	 63%	 0.82	Admission	factors	 Admission	SOFA	score,	median	(IQR)	 9	(6.5-11)	 8	(4-10)	 0.17	Admission	APACHE	II	Score,	median	(IQR)	 21	(18-26)	 23.5(18.5-29)	 0.5	%	fulfilling	criteria	for	shock	on	admission	 76%	 56%	 0.07	%	admitted	following	surgery	 30%	 23%	 0.39	%	admitted	following	trauma	 1%	 5%	 0.05	Illness	course/interventions	prior	to	endpoint	achievement	
Peak	SOFA	score,	median	(IQR)	 9	(8-12.5)	 8	(5-11)	 0.18	%	intubated	 94%	 88%	 0.88	%	with	central	venous	catheter	 90%	 88%	 0.70	%	receiving	renal	replacement	therapy	 42%	 33%	 0.37	%	with	tracheostomy	 8%	 6%	 0.7	%	with	urinary	catheter	 92%	 97%	 0.35	%	receiving	H2	antagonist/proton	pump	inhibitor	 100%	 98%	 0.14	
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%	receiving	corticosteroids	 30%	 23%	 0.58	%	receiving	a	blood	transfusion	 52%	 44%	 0.42	%	receiving	total	parenteral	nutrition	 27%	 18%	 0.26	Length	of	stay	prior	to	infection,	median	(IQR)	 6(5-7)	 5(3-8)	 0.22	Immune	profiling	 %	with	elevated	Tregs	 60%	 29%	 0.002	%	with	low	CD88	 94%	 62%	 0.001	%	with	low	HLA-DR	 85%	 55%	 0.004		
Table	S3.	Demographic	and	clinical	factors	amongst	those	with	and	without	
nosocomial	infection.		Right	hand	column	indicates	p	value	for	univariate	analysis	(regression	for	continuous/ordinal	variables	and	phi	coefficient	for	binary	categorical	variables).	
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	Variable	 P	value	 Hazard	Ratio	(95%	CI)	Overall	model		 0.037	 NA	Shock	on	admission	 0.51	 1.3	(0.6-3.2)	Admission	with	trauma	 0.65	 0.75	(0.2-2.6)	*Elevated	Tregs	 0.05	 2.1	(1.0-4.2)	Neutrophil	dysfunction	 0.05	 4.0	(1.0-19.1)	Monocyte	deactivation	 0.07	 2.4	(0.92-6.5)			Table	S4.	Cox	model	for	occurrence	of	nosocomial	infection.			
*Elevated	Treg	cells	were	expressed	as	a	time-dependent	co-variate.	NA	=	not	applicable.	
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Sample
QB PE calibration 3 2 10
quantibrite 30 3 10 	A		
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Figure	S1	Example	overlaid	flow	plots	of	QuantiBRITE	beads,	used	to	
quantify	HLA-DR-PE	expression.			Panel	A	shows	Forward	(FSC)	and	Side	(SSC)	scatter,	Panel	B	shows	histograms.	
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